Suncoast Equity Management Has $45.90 Million Position in Eli Lilly and Company $LLY

Suncoast Equity Management trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% in the 4th quarter, Holdings Channel reports. The fund owned 42,711 shares of the company’s stock after selling 536 shares during the quarter. Eli Lilly and Company comprises 4.6% of Suncoast Equity Management’s portfolio, making the stock its 8th biggest holding. Suncoast Equity Management’s holdings in Eli Lilly and Company were worth $45,900,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of LLY. Maryland Capital Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the period. 10Elms LLP boosted its position in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after acquiring an additional 24 shares during the period. Finally, Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at $33,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported highly encouraging Phase 3 data for Retevmo in early-stage lung cancer, with an 83% reduction in recurrence or death, reinforcing its cancer pipeline momentum. Article Title
• Positive Sentiment: Hanmi signed a licensing deal with Lilly for sonefpeglutide, adding another external growth opportunity to Lilly’s obesity/diabetes pipeline. Article Title
• Positive Sentiment: Investor commentary remains upbeat after Lilly’s strong Q1 results, raised full-year outlook, and recent oral obesity drug approval, all of which support the bullish growth narrative. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LLY shares. Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research note on Thursday, May 21st. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Bank of America upped their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price objective for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,105.37 on Monday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,149.10. The firm has a market cap of $1.04 trillion, a PE ratio of 39.27, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business has a fifty day moving average of $955.92 and a 200-day moving average of $1,010.09.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.